Merck to cut advertising

Categories: Big Pharma | Posted On:

Despite a recent downturn in Merck’s sales, cost-cutting has offset the effects of slowing revenues from Merck’s blockbuster drug Vioxx and recent growth in the generic market. Merck posted a five percent rise in profits and met the expected $0.81 a share.

Merck has reportedly cut back on television ads and focused on more targeted media like online Internet communities. Merck follows Pfizer’s announcement that it is reducing its sales force. Layoffs as well as expiring patents, an increase in the amount of drug recalls, and inflated sales predictions have all played a role in forcing Merck’s recent downsizing.

You reap what you sow. Big Pharma’s lack of focus on R&D and overemphasis on advertising and gaming the system to extend patent life is finally catching up with them.

eDrugSearch - save on medication costs and get free drug coupons

eDrugSearch - save on medication costs and get free drug coupons

About Cary Byrd

eDrugSearch founder, Cary Byrd, has been called an “e-health innovator” by MarketIntellNow, interviewed by top pharmaceutical industry journalists, invited to Matthew Holt’s Health 2.0 Conference and a Consumer Report's health summit, and highlighted on numerous health blogs. - Search. Compare. Save.

Leave a Reply

Join Our Free Newsletter

Please enter email id

Get a weekly dose of money-saving tips on your medications, drug side effects alerts, drug interaction warnings, free prescription coupons, late-breaking safety information and much, much more!

Share via
Copy link